Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, today announced the roll-out of its condition management programme DailyBloom IBS, India’s first integrated care plan for Irritable Bowel Syndrome (IBS). The programme is based on extensive research and is enabled by a mobile application developed in-house. DailyBloom IB focuses on a comprehensive care plan that includes diet management, psychological and physical wellness support for patients with IBS. Dr. Reddy’s has launched the programme on ‘World IBS Day’, a day that aims to increase awareness of the IBS condition, discuss misconceptions, challenges and eve stigma attached to it.

Irritable Bowel Syndrome (IBS) is a functional gastrointestinal disorder characterised by abdominal pain, bloating and altered bowel habits. Studies show that IBS leads to significant morbidity, work absenteeism, loss of productivity, economic burden to the society, and impacts the quality of life o patients.

Around 7% of the Indian population suffers from IBS. Psychological and somatoform comorbidities are often seen in IBS patients. Being a chronic condition, IBS can be managed more effectively by using an integrated care approach involving education, lifestyle changes, personalised nutrition and wellness, along with standard of care medical management.

Dr. Reddy’s DailyBloom IBS is a 14-week care plan that comes with a personalised approach to ensure that each patient’s experience is tailored to their specific needs. The journey of a patient on th care plan begins with the DailyBloom Gut Health Index, an initial assessment that captures the frequency of symptoms and impact on their quality of life.

DailyBloom IBS care plan aims to bridge the gap in the effective management of IBS by providing patients in India with seamless access to integrated care conveniently at their fingertips. DailyBloom IBS was built in consultation with a team of multi-disciplinary experts, patients and gastroenterologists and based on rigorous research over a period of 12 months. The exhaustive research process included 9,600+ minutes of doctor and patient immersions, 3,000+ observations, and understanding of 300+ pain points linked to IBS. Preliminary user experience has generated highly positive response to DailyBloom IBS.

M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s, said: “Apart from growing our core business, our strategy for India is based on the three innovative and synergistic pillars of access to novel molecules, consumer health, and digital therapeutics. Our aim is to meet unmet needs of patients and enhance standard of care where possible.

“In the digital therapeutics segment, as with the drug-free migraine management device Nerivio, DailyBloom IBS also offers a differentiated value proposition to patients. “DailyBloom IBS has been developed in-house, based on rigorous research and extensive consultation with experts including gastroenterologists. IBS is a chronic condition and its symptoms are often misdiagnosed or neglected.

Our initiative is India’s first integrated care plan for IBS. We have drawn on our three-decade old market leadership in the gastrointestinal (GI) segment consisting of trusted and established oral drug brands such as Omez, Razo, Econorm, and Redotil. We are therefore happy to offer an integrated are approach to this GI condition that aims to enhance standard of care in keeping with our purpose of ‘Good Health Can&t Wait.”